Risk-averse investors threaten drug development
Monday 16 June 2008
New drug development by the biotechnology industry is threatened by increasingly risk-averse investors and intensifying competition from generic rivals, a survey shows.
A major cause of investor wariness is the growing caution of the US Food and Drug Administration in granting marketing approval for new drugs. This in turn cuts into the time that the treatment is protected by patent, the survey, by the law firm Marks & Clerk, found.
Of the biotech and pharmaceutical executives surveyed, 90 per cent said that secondary and further funding would become harder to secure. Investors will instead focus on less-risky, later-stage drug development in an attempt to limit their risk exposure, prompting biotech companies to switch to these activities, the survey found.
Where capital is available, the terms are set to become more onerous for companies seeking investment.
The survey found that 80 per cent of respondents expected key investors to seek a bigger equity stake or to look to secure their capital against drug-makers' intellectual property assets.
Some 78 per cent of respondents stated that the climate for biotech innovation had got worse over the past year, with 89 per cent predicting that small or early-stage companies would either fail or be bought out at unattractive levels.
Competition from generic drugs manufacturers is also putting the industry under pressure, with three-quarters of respondents reporting that patents are harder to protect against generic producers than in the past.
Dr Gareth Williams, partner at Marks & Clerk and co-author of the report, said: "Biotechnology represents the future of modern medicine, where yesterday's innovators now struggle with dwindling pipelines, generic competition and a chequered R&D record.
"Whilst the long-term view has not changed, we are seeing a short to mid-term funding gap in the current climate, which poses a genuine risk to essential, early-stage research and development."
The survey is based on the views of 484 responses from senior executives in the industry, mainly in the US and the UK.
- 3 Alton Towers crash: Four seriously injured and 16 guests trapped as Smiler ride carriages collide
- 4 Ann Summers survey reveals the UK's favourite sex position
Thousands of teenage girls enduring debilitating illnesses after routine school cancer vaccination
Migrants in Kos: Photos show real tragedy after Brits abroad complain of 'awkward' holidays
British tourists complain that impoverished boat migrants are making holidays 'awkward' in Kos
Michael Gove determined to scrap the Human Rights Act – even if Scotland retains it
Threat to scrap Human Rights Act could see UK follow Nazi example, warns UN official
Church of England 'one generation away from extinction' after dramatic loss of followers
iJobs Money & Business
£30000 - £35000 per annum: Recruitment Genius: The UK's fastest growing, multi...
£70000 - £90000 per annum: Recruitment Genius: A Financial Reporting Manager i...
£23000 - £25000 per annum: Recruitment Genius: They win lots of awards for the...
£13500 - £20000 per annum: Recruitment Genius: This nationwide enforcement com...